Other Clinical Trial - Efficacy & Safety of Ularitide for the Treatment of

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of a continuous intravenous (IV) ularitide infusion on the clinical status and outcome of patients with acute decompensated heart failure (ADHF).

Clinical Trial Description

The objective of the TRUE-AHF study is to evaluate the effect of a 48-h continuous IV infusion of ularitide (15 ng/kg/min) versus placebo on the clinical status of patients with acute decompensated heart failure (ADHF).

The study drug will be administered in addition to the standard treatment. The nature of standard therapy will be carried out according to the clinical judgment of the Investigator and may include vasodilator, inotropic, and diuretic drugs, as clinically indicated.

There are two co-primary endpoints for this study. Co-primary endpoint 1 will be a hierarchical clinical composite variable that includes a patient-centered assessment of clinical progress, an assessment of lack of improvement or worsening of HF requiring a pre-specified intervention, and death.

The endpoint is intended to mimic the assessment that would be carried out by a physician caring for the patient. If, during the 48 h infusion, a patient's clinical course deteriorates because he/she dies, fails to improve or develops worsening HF requiring a pre-specified intervention or if the patient considers his/her general clinical status as moderately or markedly worse, the patient will be considered to be "worse". If the patient considers his/her general clinical status as moderately or markedly improved and if such improvement is sustained without fulfilling the criteria for "worse" throughout the 48-h infusion (from 0 h to 48 h), the patient will be considered to be "improved". If the patient is neither improved nor worse, the patient's clinical status will be considered to be "unchanged".

Co-primary efficacy endpoint 2 evaluates freedom from cardiovascular mortality during follow up after randomization, for the entire duration of the trial. ;

Study Design

Related Conditions & MeSH terms

Acute Decompensated Heart Failure
Heart Failure

Clinical Trial Details

NCT number	NCT01661634
Study type	Interventional
Source	Cardiorentis
Contact
Status	Completed
Phase	Phase 3
Start date	July 2012
Completion date	March 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04049045` - Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure	Phase 2
Active, not recruiting	`NCT05100836` - SURPASS Impella 5.5 Study
Recruiting	`NCT02898181` - Low Level Tragus Stimulation in Acute Decompensated Heart Failure	N/A
Completed	`NCT02823626` - High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
Completed	`NCT02196038` - A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients	N/A
Completed	`NCT02248831` - Evaluation of Cardiopulmonary Diseases by Ultrasound	N/A
Completed	`NCT00693745` - Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF	N/A
Not yet recruiting	`NCT04391231` - HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial	Phase 4
Recruiting	`NCT05206422` - DORAYA-HF Early Feasibility Study	N/A
Recruiting	`NCT01960218` - Gas Exchange for Predicting Hospital Heart Failure Readmissions	N/A
Terminated	`NCT00904488` - Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure	Phase 4
Terminated	`NCT02620384` - Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.	Phase 3
Completed	`NCT04318093` - Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure	Phase 2
Recruiting	`NCT06161649` - Mobile Education System to Improve Disease Knowledge, Self-efficacy and Quality of Life in Patients With Heart Failure	N/A
Completed	`NCT02289508` - Role of USCOM in Adult Patients With Heart Failure	N/A
Terminated	`NCT01457053` - Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics	N/A
Completed	`NCT04877652` - DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
Completed	`NCT03505788` - Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)	Phase 4
Completed	`NCT03146754` - A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE)	N/A
Terminated	`NCT05346653` - The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure — TRUE-AHF

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms